$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

$tcrt Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000119312513112464 Filed on March 18, 2013

Income Statement

Concept	2013 Q1	2012 Q4	2012
Revenue	$200.0K	$200.0K	$800.0K
YoY Change	0.0%	0.0%	19.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.670M	$4.060M	$19.52M
YoY Change	-3.71%	2.27%	30.31%
% of Gross Profit
Research & Development	$19.11M	$34.98M	$83.45M
YoY Change	36.66%	176.52%	46.18%
% of Gross Profit
Depreciation & Amortization	$200.0K	$190.0K	$660.0K
YoY Change	66.67%	90.0%	144.44%
% of Gross Profit
Operating Expenses	$19.11M	$39.04M	$83.45M
YoY Change	36.66%	134.9%	46.18%
Operating Profit	-$23.58M	-$38.84M	-$102.2M
YoY Change	26.57%	136.6%	43.09%
Interest Expense	$10.79M	$8.570M	$6.050M
YoY Change	-285.71%	171.2%	-20.18%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$50.00K	-$13.00K
YoY Change	-84.62%	400.0%	-133.33%
Pretax Income	-$12.80M	-$30.23M	-$96.13M
YoY Change	-47.69%	128.32%	50.72%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.80M	-$30.23M	-$96.13M
YoY Change	-47.7%	128.22%	50.73%
Net Earnings / Revenue	-6399.5%	-15112.5%	-12016.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.15	-$0.37	-$1.22
COMMON SHARES
Basic Shares Outstanding	83.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q4	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.70M	$73.30M	$73.30M
YoY Change	-56.48%	-29.99%	-29.99%
Cash & Equivalents	$55.66M	$73.31M	$73.30M
Short-Term Investments
Other Short-Term Assets	$4.800M	$6.900M	$6.900M
YoY Change	-55.56%	430.77%	430.77%
Inventory
Prepaid Expenses
Receivables	$100.0K	$100.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$60.56M	$80.28M	$80.30M
YoY Change	-56.37%	-24.34%	-24.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.909M	$1.994M	$2.000M
YoY Change	62.19%	74.76%	81.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$743.0K	$1.001M	$1.100M
YoY Change	-6.42%	29.83%	22.22%
Total Long-Term Assets	$2.785M	$3.128M	$3.100M
YoY Change	35.06%	56.17%	55.0%
TOTAL ASSETS
Total Short-Term Assets	$60.56M	$80.28M	$80.30M
Total Long-Term Assets	$2.785M	$3.128M	$3.100M
Total Assets	$63.35M	$83.40M	$83.40M
YoY Change	-55.03%	-22.85%	-22.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$983.0K	$1.509M	$1.500M
YoY Change	-50.45%	-12.62%	-11.76%
Accrued Expenses	$18.52M	$16.52M	$16.50M
YoY Change	60.58%	52.63%	52.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.36M	$18.86M	$18.90M
YoY Change	42.09%	41.17%	41.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.174M	$0.00	$16.10M
YoY Change	-91.37%	-100.0%	-30.3%
Total Long-Term Liabilities	$2.174M	$0.00	$16.10M
YoY Change	-91.37%	-100.0%	-30.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.36M	$18.86M	$18.90M
Total Long-Term Liabilities	$2.174M	$0.00	$16.10M
Total Liabilities	$25.45M	$34.96M	$35.00M
YoY Change	-41.04%	-4.22%	-4.11%
SHAREHOLDERS EQUITY
Retained Earnings		-$283.7M
YoY Change
Common Stock	$327.6M	$325.3M
YoY Change	8.23%	31.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.89M	$48.45M	$48.40M
YoY Change
Total Liabilities & Shareholders Equity	$63.35M	$83.40M	$83.40M
YoY Change	-55.03%	-22.85%	-22.85%

Cashflow Statement

Concept	2013 Q1	2012 Q4	2012
OPERATING ACTIVITIES
Net Income	-$12.80M	-$30.23M	-$96.13M
YoY Change	-47.7%	128.22%	50.73%
Depreciation, Depletion And Amortization	$200.0K	$190.0K	$660.0K
YoY Change	66.67%	90.0%	144.44%
Cash From Operating Activities	-$18.24M	-$21.50M	-$78.83M
YoY Change	-29.45%	56.36%	102.99%
INVESTING ACTIVITIES
Capital Expenditures	$114.0K	$80.00K	$1.559M
YoY Change	-25.97%	-77.14%	34.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$114.0K	-$80.00K	-$1.559M
YoY Change	-25.97%	-77.14%	34.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$246.0K		$546.0K
YoY Change	-99.53%		99.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	706.0K	-450.0K	48.98M
YoY Change	-98.57%	275.0%	-41.9%
NET CHANGE
Cash From Operating Activities	-18.24M	-21.50M	-78.83M
Cash From Investing Activities	-114.0K	-80.00K	-1.559M
Cash From Financing Activities	706.0K	-450.0K	48.98M
Net Change In Cash	-17.65M	-22.03M	-31.41M
YoY Change	-175.77%	54.92%	-170.86%
FREE CASH FLOW
Cash From Operating Activities	-$18.24M	-$21.50M	-$78.83M
Capital Expenditures	$114.0K	$80.00K	$1.559M
Free Cash Flow	-$18.36M	-$21.58M	-$80.39M
YoY Change	-29.43%	53.05%	101.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2004Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9017538	shares
CY2004Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.00	pure
CY2006Q2	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0501	pure
CY2006Q2	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	4.63
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2007Q1	ziop	Class Of Warrant Term ClassOfWarrantTerm	P5Y
CY2007Q1	ziop	Exercise Price Of Warrants ExercisePriceOfWarrants	5.75
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	0.93	pure
CY2007Q1	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0471	pure
CY2007Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.225
CY2007Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	25111	shares
CY2010Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q2	ziop	Investment Option Exercise Period InvestmentOptionExercisePeriod	P30D
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83703934	shares
CY2004Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2006Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2006Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2006Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2006Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2006Q2	ziop	Shares Authorized SharesAuthorized	280000000	shares
CY2011Q1	ziop	Collaborative Arrangement Agreement Research Funding Period CollaborativeArrangementAgreementResearchFundingPeriod	P75M
CY2005Q2	ziop	Commission Rate CommissionRate	0.07	pure
CY2010Q2	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.00
CY2003Q3	us-gaap	Stockholders Equity StockholdersEquity	500000
CY2003Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1001949	shares
CY2003Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2005Q3	ziop	Percentage Of Outstanding Common Shares On Fully Diluted Basis PercentageOfOutstandingCommonSharesOnFullyDilutedBasis	0.968	pure
CY2009Q3	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	1.825
CY2009Q3	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	1.825
CY2011Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3636926	shares
CY2011Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	4.80
CY2011Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3636926	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	396154064
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60392000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	348753	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4566935	shares
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1313000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2466000
CY2003Q4	us-gaap	Stockholders Equity StockholdersEquity	340000
CY2011Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	4.80
CY2011Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.75
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.09	pure
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0439	pure
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	26533000
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	30370000
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2004Q4	us-gaap	Stockholders Equity StockholdersEquity	-144000
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2004Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2005Q4	us-gaap	Stockholders Equity StockholdersEquity	7202000
CY2005Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2005Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2005Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2005Q4	ziop	Preferred Stock Conversion Rate PreferredStockConversionRate	0.500974	pure
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	6739000
CY2008Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	-83495000
CY2008Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	18866000
CY2008Q4	ziop	Warrants Liability WarrantsLiability	72000
CY2009Q4	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	3.10
CY2009Q4	ziop	Warrants To Purchase Shares WarrantsToPurchaseShares	0.5	shares
CY2009Q4	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	3.10
CY2009Q4	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1 NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1	-72000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	28104000
CY2009Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	238000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.30
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.82
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48839000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1467167	shares
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3534686	shares
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	5	Y
CY2009Q4	ziop	Class Of Warrant Term ClassOfWarrantTerm	P5Y
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.05	pure
CY2009Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0214	pure
CY2009Q4	ziop	Estimated Fair Value Of Warrant EstimatedFairValueOfWarrant	22900000
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	30553000
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.30
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	246519000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74793000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2911186	shares
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2011Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	12611000
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1131000
CY2011Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	79000
CY2011Q4	us-gaap	Liabilities Liabilities	36501000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1727000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	771000
CY2011Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	195000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	71607000
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	156000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	347000
CY2011Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4232000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2011Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	399000
CY2011Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	263000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.21
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69206044	shares
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18283000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	306000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.34
CY2011Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	187592000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19425000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	103736000
CY2011Q4	us-gaap	Assets Assets	108108000
CY2011Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	307000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.08
CY2011Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	91000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	702000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108108000
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	890000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104713000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69206044	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	950906	shares
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10821000
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	15000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13363000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5138486	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	69000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1325000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1141000
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	180000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3533000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	106105000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74793000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	ziop	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	170000
CY2011Q4	ziop	Computer And Office Equipment Gross ComputerAndOfficeEquipmentGross	1021000
CY2011Q4	ziop	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	8885000
CY2011Q4	ziop	Warrant Liabilities Fair Value Disclosure WarrantLiabilitiesFairValueDisclosure	19425000
CY2011Q4	ziop	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	767000
CY2011Q4	ziop	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	6913000
CY2011Q4	ziop	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	1093000
CY2011Q4	ziop	Deferred Tax Assets Start Up And Organizational Costs DeferredTaxAssetsStartUpAndOrganizationalCosts	40047000
CY2011Q4	ziop	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	6400000
CY2012Q1	ziop	Common Stock Price Per Share1 CommonStockPricePerShare1	5.20
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6912000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1200000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3918000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1706020	shares
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	325177000
CY2012Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	474000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	122343000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1001000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3683786	shares
CY2012Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	439000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48445000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	997000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	153000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9900000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	903000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3972000
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1388000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	11000
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	856000
CY2012Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	585000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12962000
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11197454	shares
CY2012Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	6909000
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	835000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1236000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.56
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3973000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83236840	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7096125	shares
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1209000
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	58000
CY2012Q4	us-gaap	Liabilities Liabilities	34959000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1509000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	275000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42715000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	998000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.37
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	283724000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	501000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	72002000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283700000
CY2012Q4	us-gaap	Assets Assets	83404000
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	452000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.56
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	133000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	991000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83404000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3944000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1357000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	691000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73306000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83236840	shares
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	424000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	733739	shares
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16516000
CY2012Q4	us-gaap	Significant Purchase Commitment Remaining Minimum Amount Committed SignificantPurchaseCommitmentRemainingMinimumAmountCommitted	29000000
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	39000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18864000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7147303	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	83000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	400000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Stock Volatility ClassOfWarrantOrRightFairValueAssumptionStockVolatility	1.34	pure
CY2012Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate	0.0393	pure
CY2012Q4	ziop	Warrant Liabilities Fair Value Disclosure WarrantLiabilitiesFairValueDisclosure	12962000
CY2004Q4	ziop	Warrant Exercise Price WarrantExercisePrice	4.75
CY2004Q4	ziop	Related Party Transactions Fees Payable In Cash RelatedPartyTransactionsFeesPayableInCash	60000
CY2006Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	180000
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2733000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	80276000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	122343000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5567000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1924000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994000
CY2012Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Life ClassOfWarrantOrRightFairValueAssumptionExpectedLife	7	Y
CY2012Q4	ziop	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	331000
CY2012Q4	ziop	Computer And Office Equipment Gross ComputerAndOfficeEquipmentGross	1552000
CY2012Q4	ziop	Deferred Tax Assets Tax Credit Carryforwards Research And Development DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment	18388000
CY2012Q4	ziop	Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield	0.00	pure
CY2012Q4	ziop	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	3217000
CY2012Q4	ziop	Net Operating Loss Carryforward Excess Tax Deduction Related To Stock Based Compensation NetOperatingLossCarryforwardExcessTaxDeductionRelatedToStockBasedCompensation	4100000
CY2012Q4	ziop	Estimated Fair Value Of Warrant EstimatedFairValueOfWarrant	3500000
CY2012Q4	ziop	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	9628000
CY2012Q4	ziop	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	411000
CY2012Q4	ziop	Deferred Tax Assets Start Up And Organizational Costs DeferredTaxAssetsStartUpAndOrganizationalCosts	44262000
CY2012Q4	ziop	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	13270000
	us-gaap	Equity Issuance Dates EquityIssuanceDates	2003-09-09
	us-gaap	Net Income Loss NetIncomeLoss	-160000
CY2003Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000
CY2010Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32800000
CY2010Q2	us-gaap	Banking Fees And Commissions BankingFeesAndCommissions	2200000
CY2010Q2	ziop	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1050000	shares
CY2010Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7000000	shares
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63500000
CY2011Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	11040000	shares
CY2006Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37000000
CY2006Q2	us-gaap	Payments For Commissions PaymentsForCommissions	1700000
CY2006Q2	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	799126	shares
CY2006Q2	ziop	Company Allocation Of Stock Units To Match Stock Unit Purchase CompanyAllocationOfStockUnitsToMatchStockUnitPurchase	0.30	pure
CY2006Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7991256	shares
CY2006Q2	ziop	Term Of Warrants Issued To Investor TermOfWarrantsIssuedToInvestor	P5Y
CY2006Q2	ziop	Common Stock Exercise Price Per Share CommonStockExercisePricePerShare	5.56
CY2004Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	251000
CY2004Q4	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	62621	shares
CY2004Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4500000
CY2007Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30900000
CY2007Q1	us-gaap	Payments For Commissions PaymentsForCommissions	1000000
CY2007Q1	ziop	Company Allocation Of Stock Units To Match Stock Unit Purchase CompanyAllocationOfStockUnitsToMatchStockUnitPurchase	0.20	pure
CY2007Q1	ziop	Warrant Exercise Price WarrantExercisePrice	5.75
CY2007Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	5910049	shares
CY2007Q1	ziop	Term Of Warrants Issued To Investor TermOfWarrantsIssuedToInvestor	P5Y
CY2007Q1	ziop	Term Of Warrants TermOfWarrants	P5Y
CY2007Q1	ziop	Common Stock Purchase CommonStockPurchase	21244	shares
CY2007Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	104000
CY2007Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000
CY2005Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18100000
CY2005Q2	ziop	Class Of Warrant Or Right Exercise Period ClassOfWarrantOrRightExercisePeriod	P7Y
CY2005Q2	ziop	Costs Reimbursed CostsReimbursed	50000
CY2005Q2	ziop	Warrant Exercise Price As Percent Of Market Value WarrantExercisePriceAsPercentOfMarketValue	1.10	pure
CY2005Q2	ziop	Aggregate Consideration Value Finalization Period After Closing AggregateConsiderationValueFinalizationPeriodAfterClosing	P3Y
CY2005Q3	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	425000
CY2009Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5100000
CY2009Q3	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	455000
CY2009Q3	ziop	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	4600000
CY2009Q3	ziop	Common Stock Shares Sold CommonStockSharesSold	2772337	shares
CY2009Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5100000
CY2009Q3	ziop	Placement Agents Warrant Percentage Of Shares Sold PlacementAgentsWarrantPercentageOfSharesSold	0.05	pure
CY2009Q3	ziop	Common Stock Shares Sold CommonStockSharesSold	2772337	shares
CY2011Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11645928
CY2011Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17500000
CY2011Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	2426235	shares
CY2011Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11600000
CY2011Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	2426235	shares
CY2010Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35000000
CY2010Q2	ziop	Common Stock Shares Sold CommonStockSharesSold	7000000	shares
CY2009Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	45200000
CY2009Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	2800000
CY2009Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	48000000
CY2009Q4	ziop	Common Stock Shares Sold CommonStockSharesSold	15484000	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-299196000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	10771000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1509000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4701000
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	10771000
	us-gaap	Share Based Compensation ShareBasedCompensation	20181000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	300663000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	352000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2867000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations of Credit Risk</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</font></p> </div>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	212345000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	299571000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2574000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1373000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-221640000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4625000
	us-gaap	Income Taxes Paid IncomeTaxesPaid
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3533000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4626000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	73306000
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	439000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	88318000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6912000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13079000
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	500000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4200000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	134000
	us-gaap	Revenues Revenues	1467000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-57000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1001000
	us-gaap	Interest Paid InterestPaid
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted		shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	36151000
	us-gaap	Net Income Loss NetIncomeLoss	-283724000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	58000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s most significant estimates and judgments used in the preparation of our financial statements are:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Clinical trial expenses;</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Fair value measurements for stock based compensation and warrants; and</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Income taxes.</font></p> </td> </tr> </table> </div>
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	16760000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	16516000
	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	270726000
	ziop	Issuance Of Warrants To Placement Agent In Public Offering IssuanceOfWarrantsToPlacementAgentInPublicOffering	47276000
CY2005	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45000
CY2005	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-9517000
CY2005	ziop	Stock Issued During Period Value Preferred Stock And Common Stock Warrants StockIssuedDuringPeriodValuePreferredStockAndCommonStockWarrants	1683000
CY2005	ziop	Stock Issued During Period Value Convertible Preferred New Issues StockIssuedDuringPeriodValueConvertiblePreferredNewIssues	15077000
CY2005	ziop	Stock Issued Issuance Costs StockIssuedIssuanceCosts	1340000
CY2005	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1683000
CY2005	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	12500	shares
CY2005	ziop	Convertible Preferred Stock Conversion Date ConvertiblePreferredStockConversionDate	2005-09-13
CY2005	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	50000	shares
CY2006	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13092000
CY2006	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2777000
CY2006	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-17857000
CY2006	ziop	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	37500	shares
CY2007	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5433000
CY2007	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000
CY2007	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120000
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-26608000
CY2007	ziop	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod	25111	shares
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2181000
CY2009	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	380000
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-7649000
CY2009	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	279000
CY2009	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	8206520	shares
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	880000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-24546000
CY2010	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8889000
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-758000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.000	pure
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	765000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3637000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	115000	shares
CY2010	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-8889000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0113	pure
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	3637000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.55
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015	pure
CY2010	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	24546000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.36
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2010	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	196167	shares
CY2010	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	49000
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1668000
CY2010	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2010	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1668000
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	188000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19694000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-186000
CY2010	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1182164	shares
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.19
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043	pure
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11553000
CY2010	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-24000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8920	pure
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11636000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.19
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	70000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.15
CY2010	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	72000
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12910000
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31433000
CY2010	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	21000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64584	shares
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9060	pure
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.40
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	398000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2010	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	41000
CY2010	us-gaap	Revenues Revenues
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.158	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.001	pure
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27000
CY2010	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	122000
CY2010	us-gaap	Interest Paid InterestPaid
CY2010	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46003996	shares
CY2010	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	37000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0275	pure
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20827830	shares
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-32670000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1293000	shares
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	51250	shares
CY2010	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1277000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.26
CY2010	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	32804000
CY2010	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	121000
CY2010	ziop	Share Based Compensation Tax Expense Benefit ShareBasedCompensationTaxExpenseBenefit
CY2010	ziop	Conversion Of Warrants To Common Stock ConversionOfWarrantsToCommonStock	39225
CY2010	ziop	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod	6904	shares
CY2010	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	95505	shares
CY2010	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	-0.154	pure
CY2010	ziop	Share Based Compensation Net Of Tax ShareBasedCompensationNetOfTax	3637000
CY2010	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	0
CY2010	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	-0.093	pure
CY2010	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.008	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-71400000
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7583000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	696000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.111	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M7D
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2759000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	848406	shares
CY2011	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	7583000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0109	pure
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	2759000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.65
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000	pure
CY2011	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	72067000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.01
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38835000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1156000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060	pure
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	479666	shares
CY2011	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	303000
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	274000
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	273000
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	268000
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	980000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4333000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	229586	shares
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.04
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1156000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44321000
CY2011	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	109000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8326	pure
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14984000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.56
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	889000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.52
CY2011	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12399000
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57083000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	84312000
CY2011	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	38000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	843083	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8729	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.85
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	647000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2011	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	4000
CY2011	us-gaap	Revenues Revenues	667000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.542	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.005	pure
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	407000
CY2011	us-gaap	Interest Paid InterestPaid
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66003789	shares
CY2012	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0501	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.097	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M11D
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2011	ziop	Share Based Compensation Net Of Tax ShareBasedCompensationNetOfTax	2759000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0269	pure
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19206656	shares
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	17457000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-63778000
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	79000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1894300	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	16667	shares
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8283000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.04
CY2011	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	71207000
CY2011	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	12701000
CY2011	ziop	Share Based Compensation Tax Expense Benefit ShareBasedCompensationTaxExpenseBenefit
CY2011	ziop	Conversion Of Warrants To Common Stock ConversionOfWarrantsToCommonStock	2377571
CY2011	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	2516968	shares
CY2011	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0.000	pure
CY2011	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	0
CY2011	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.037	pure
CY2011	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.000	pure
CY2004	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	251000
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-5687000
CY2004	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	62621	shares
CY2008	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1600000
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-25231000
CY2012	dei	Trading Symbol TradingSymbol	ZIOP
CY2012	dei	Entity Registrant Name EntityRegistrantName	ZIOPHARM ONCOLOGY INC
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001107421
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-102169000
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	6050000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	45823	shares
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-218000
CY2012	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	6050000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y3M11D
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0079	pure
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	4880000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.36
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000	pure
CY2012	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	102969000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.70
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.22
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8300	shares
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	412000
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	546000
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	292533	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8353	pure
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.34
CY2012	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	50000000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4880000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	258032	shares
CY2012	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	546000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	658000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78832000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1559000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-800000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	351829	shares
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.61
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046	pure
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1559000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31407000
CY2012	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	244000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8336	pure
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19523000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.32
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5599000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.39
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M23D
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	330000
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83446000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48984000
CY2012	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	266000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	47600000
CY2012	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	43000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M4D
CY2012	us-gaap	Revenues Revenues	800000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.494	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010	pure
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-48000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	230000
CY2012	us-gaap	Interest Paid InterestPaid
CY2012	us-gaap	Payments For Commissions PaymentsForCommissions	1700000
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	78546112	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0113	pure
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19078496	shares
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18694000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-96132000
CY2012	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-21000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2309650	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	123370	shares
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5695000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.06
CY2012	ziop	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	49170000
CY2012	ziop	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	742000
CY2012	ziop	Share Based Compensation Tax Expense Benefit ShareBasedCompensationTaxExpenseBenefit
CY2012	ziop	Conversion Of Warrants To Common Stock ConversionOfWarrantsToCommonStock	259660
CY2012	ziop	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	553914	shares
CY2012	ziop	Effective Income Tax Rate Reconciliation Uncertain Tax Positions EffectiveIncomeTaxRateReconciliationUncertainTaxPositions	0.000	pure
CY2012	ziop	Placement Agents Warrant Percentage Of Shares Sold PlacementAgentsWarrantPercentageOfSharesSold	0.10	pure
CY2012	ziop	Warrants To Purchase Aggregate Shares Of Common Stock WarrantsToPurchaseAggregateSharesOfCommonStock	799126	shares
CY2012	ziop	Share Based Compensation Net Of Tax ShareBasedCompensationNetOfTax	4880000
CY2012	ziop	Warrant Exercise Price WarrantExercisePrice	5.09
CY2012	ziop	Minimum Percentage Of Purchase Committed Under Contract MinimumPercentageOfPurchaseCommittedUnderContract	0.1999	pure
CY2012	ziop	Milestone Payment Under License Agreement MilestonePaymentUnderLicenseAgreement	250000
CY2012	ziop	Adjustments To Additional Paid In Capital Conversion Of Warrants AdjustmentsToAdditionalPaidInCapitalConversionOfWarrants	1700000
CY2012	ziop	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.021	pure
CY2012	ziop	Term Of Warrants TermOfWarrants	P7Y
CY2012	ziop	Percentage Of Net Proceeds Of Offering PercentageOfNetProceedsOfOffering	0.40	pure
CY2012	ziop	Expense Reimbursement ExpenseReimbursement	100000
CY2012	ziop	Effective Income Tax Rate Reconciliation Federal Research And Development Tax Grant EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentTaxGrant	0.000	pure
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52600000
CY2012Q1	ziop	Common Stock Shares Sold CommonStockSharesSold	10114401	shares
CY2009Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48000000
CY2011Q1	us-gaap	Revenues Revenues	67000
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-39008000
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12848000
CY2011Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	2115000
CY2009Q4	ziop	Common Stock Shares Sold CommonStockSharesSold	15484000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.75
	us-gaap	Net Income Loss NetIncomeLoss	-15364000
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27926000
CY2011Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-11080000
CY2011Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	27993000
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2011Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	13048000
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2011Q2	us-gaap	Revenues Revenues	200000
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-10724000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18633000
CY2012Q1	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-5811000
CY2012Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	18833000
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2012Q1	us-gaap	Revenues Revenues	200000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-24470000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22966000
CY2012Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-650000
CY2012Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23166000
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q2	us-gaap	Revenues Revenues	200000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-23613000
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14209000
CY2011Q3	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	13388000
CY2011Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14409000
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2011Q3	us-gaap	Revenues Revenues	200000
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-802000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21727000
CY2012Q3	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	3945000
CY2012Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	21927000
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2012Q3	us-gaap	Revenues Revenues	200000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-17824000
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16417000
CY2011Q4	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	3160000
CY2011Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16617000
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2011Q4	us-gaap	Revenues Revenues	200000
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-13244000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-38843000
CY2012Q4	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	8566000
CY2012Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	39043000
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2012Q4	us-gaap	Revenues Revenues	200000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-30225000

Files In Submission

Name	View Source	Status
0001193125-13-112464-index-headers.html	Edgar Link	pending
0001193125-13-112464-index.html	Edgar Link	pending
0001193125-13-112464.txt	Edgar Link	pending
0001193125-13-112464-xbrl.zip	Edgar Link	pending
d490342d10k.htm	Edgar Link	pending
d490342dex231.htm	Edgar Link	pending
d490342dex311.htm	Edgar Link	pending
d490342dex312.htm	Edgar Link	pending
d490342dex321.htm	Edgar Link	pending
d490342dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g490342g61c97.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ziop-20121231.xml	Edgar Link	completed
ziop-20121231.xsd	Edgar Link	pending
ziop-20121231_cal.xml	Edgar Link	unprocessable
ziop-20121231_def.xml	Edgar Link	unprocessable
ziop-20121231_lab.xml	Edgar Link	unprocessable
ziop-20121231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

2013 Q1 Form 10-K Financial Statement

#000119312513112464 Filed on March 18, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT Alaunos Therapeutics, Inc. Stock $tcrt

2013 Q1 Form 10-K Financial Statement

#000119312513112464 Filed on March 18, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt